Oral Session 1-7C Multiple Myeloma: Multicenter Clinical Trials

[OS1-7C-3] Elotuzumab plus len/dex for RRMM: analysis of Japanese patients in ELOQUENT-2

Masafumi Taniwaki¹, Kazutaka Sunami², Kenshi Suzuki³, Kazuteru Ohashi⁴, Shinsuke Iida⁵, Shinichiro Okamoto⁶, Hiroshi Handa⁷, Kosei Matsue⁸, Suresh Shelat⁹, Oumar Sy⁹, Masafumi Miyoshi¹⁰, Morio Matsumoto¹¹ (1.University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan, 2.National Hospital Organization Okayama Medical Center, Okayama, Japan, 3.Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, 4.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 5.Department of Hematology, Nagoya City University Hospital, Nagoya, Japan, 6.Department of Hematology, Keio University Hospital, Tokyo, Japan, 7.Department of Hematology, Gunma University Hospital, Maebashi, Japan, 8.Department of Hematology, Kameda Medical Center, Kamogawa, Japan, 9.Bristol-Myers Squibb, Princeton, NJ, USA, 10.Bristol-Myers Squibb K.K., Tokyo, Japan, 11.National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan)